Adrian Jones Biography and Net Worth

Director of T2 Biosystems


Adrian Jones is the Director of T2 Biosystems.

What is Adrian M. Jones' net worth?

The estimated net worth of Adrian M. Jones is at least $79.66 million as of June 30th, 2023. Jones owns 50,099,392 shares of T2 Biosystems stock worth more than $79,658,033 as of October 10th. This net worth evaluation does not reflect any other investments that Jones may own. Learn More about Adrian M. Jones' net worth.

How do I contact Adrian M. Jones?

The corporate mailing address for Jones and other T2 Biosystems executives is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. T2 Biosystems can also be reached via phone at (781) 761-4646 and via email at [email protected]. Learn More on Adrian M. Jones' contact information.

Has Adrian M. Jones been buying or selling shares of T2 Biosystems?

Adrian M. Jones has not been actively trading shares of T2 Biosystems during the past quarter. Most recently, on Thursday, May 20th, Adrian M. Jones bought 51 shares of T2 Biosystems stock. The stock was acquired at an average cost of $80.00 per share, with a total value of $4,080.00. Learn More on Adrian M. Jones' trading history.

Who are T2 Biosystems' active insiders?

T2 Biosystems' insider roster includes Michael Gibbs (General Counsel), Adrian Jones (Director), and John McDonough (Director). Learn More on T2 Biosystems' active insiders.

Are insiders buying or selling shares of T2 Biosystems?

During the last twelve months, insiders at the medical equipment provider sold shares 1 times. They sold a total of 55 shares worth more than $133.10. The most recent insider tranaction occured on September, 13th when Director David B Elsbree sold 55 shares worth more than $133.10. Insiders at T2 Biosystems own 0.1% of the company. Learn More about insider trades at T2 Biosystems.

Information on this page was last updated on 9/13/2024.

Adrian M. Jones Insider Trading History at T2 Biosystems

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2021Buy51$80.00$4,080.00View SEC Filing Icon  
3/25/2021Buy6$93.00$558.00View SEC Filing Icon  
See Full Table

Adrian M. Jones Buying and Selling Activity at T2 Biosystems

This chart shows Adrian M Jones's buying and selling at T2 Biosystems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

T2 Biosystems Company Overview

T2 Biosystems logo
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $1.59
Low: $1.55
High: $1.64

50 Day Range

MA: $2.93
Low: $1.57
High: $5.03

2 Week Range

Now: $1.59
Low: $1.54
High: $31.50

Volume

150,967 shs

Average Volume

261,393 shs

Market Capitalization

$13.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31